<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Cardiovascular Systems Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/cardiovascular-systems-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CSII) Cardiovascular Systems Gets FDA Approval</title>
		<link>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084</link>
		<comments>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084#comments</comments>
		<pubDate>Sat, 16 Jan 2010 00:26:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cardiovascular Systems Inc]]></category>
		<category><![CDATA[CSII]]></category>
		<category><![CDATA[ev3 Inc]]></category>
		<category><![CDATA[EVVV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25084</guid>
		<description><![CDATA[Cardiovascular Systems, Inc. (CSII) recently received the U.S. Food and Drug Administration’s (FDA) conditional Investigational Device Exemption (IDE) approval. The approval is meant to evaluate the safety and effectiveness of the company’s Diamondback 360 degree System used to treat calcified coronary lesions. Cardiovascular Systems is now authorized to begin its pivotal trial, ORBIT II, in early 2010 and initially enroll up to 100 patients at as many as 50 U.S. sites. The Diamondback 360 degree Orbital Atherectomy System is a minimally invasive catheter system used in the treatment of peripheral arterial disease (PAD). It has been estimated that the peripheral arterial disease affects eight to twelve million people. It is caused by the accumulation of plaque in peripheral arteries (commonly the pelvis or leg), thus reducing blood flow. Diamondback 360 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/15/csii-cardiovascular-systems-gets-fda-approval/25084/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

